Biofil Chemicals and Pharmaceuticals Limited , a company listed on the Bombay Stock Exchange (BSE), has paid a fine of Rs 4,24,823.60 to BSE Limited under protest. The fine was imposed due to alleged non-compliance with Regulation 17(1)(c) of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations.

Fine Details and Company's Response

The fine imposed by BSE was broken down as follows:

The company had previously filed waiver applications with both the National Stock Exchange (NSE) and BSE. Despite these applications, BSE proceeded with the fines. Biofil Chemicals and Pharmaceuticals made the payment on December 02, while maintaining its stance of protest against the imposed penalties.

Impact on Company Operations

In its disclosure, the company stated that there is no material impact on its financial or operational activities due to this fine. This assertion is supported by the company's recent balance sheet data, which shows growth in various financial metrics.

Financial Position

A look at the company's balance sheet reveals:

Note: All financial figures are in crore rupees

The company's financial position appears to be stable, with growth in both assets and equity over the past year. This supports the company's statement that the fine does not materially impact its financial standing.

Compliance and Regulatory Environment

This incident highlights the strict regulatory environment in which listed companies operate in India. It underscores the importance of adhering to SEBI's LODR regulations, particularly Regulation 17(1)(c), which likely pertains to board composition or related governance matters.

While Biofil Chemicals and Pharmaceuticals has paid the fine, its decision to do so under protest suggests that the company may continue to seek relief or clarification on the alleged non-compliance. This situation serves as a reminder for all listed entities to maintain vigilance in their regulatory compliance efforts.

As the company moves forward, stakeholders will likely be watching closely to see if there are any further developments regarding this regulatory issue and how it might affect the company's governance practices in the future.

Biofil Chemicals and Pharmaceuticals Limited has reported a significant turnaround in profitability for the quarter ended September 30, 2025, despite a notable decline in revenue. The company's board approved the unaudited financial results for Q2 FY2026 on November 13, 2025.

Financial Highlights

• Revenue: The company's revenue from operations decreased to Rs 199.73 crore in Q2 FY2026, down from Rs 334.02 crore in the corresponding quarter of the previous year, marking a 40.20% year-on-year decline.

• Profitability: Despite the revenue drop, Biofil Chemicals posted a net profit of Rs 241.10 crore for the quarter, compared to a loss of Rs 244.19 crore in the same period last year, representing a remarkable turnaround in the company's bottom line.

• Earnings Per Share (EPS): The basic and diluted EPS for the quarter stood at Rs 1.48, a significant improvement from Rs 0.01 in Q2 FY2025.

Segment Performance

The company operates in two primary segments:

1. Pharma Products
2. Chemicals Division

However, specific segment-wise revenue figures were not provided in the available data.

Balance Sheet Overview

As of September 30, 2025:

Conclusion

Biofil Chemicals and Pharmaceuticals Limited has demonstrated resilience in its financial performance for Q2 FY2026. The company's ability to generate substantial profits despite a considerable drop in revenue suggests effective cost management or potentially diversified income streams. Investors and analysts may seek further clarification on the factors contributing to this performance during the next earnings call or investor presentation.

Note: All figures are in Indian Rupees (INR) and have been reported as per the Indian Accounting Standards (Ind-AS).